TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Peri-incisional Pregabalin for Postoperative Pain Attenuation and Analgesics Spare in Elective Neurosurgical Patients: A Randomized, Comparative, Placebo-controlled, Double Blind Study
Brief Summary: Background:

Proper pain relief is a major concern of patients worldwide. Preoperatively, one of the most common questions asked by patients pertains to the amount of pain they will experience after surgery how long it will last and how good will it be controlled. Pain concerns the surgical team as well, because of its correlation with clinical outcomes and patients' satisfaction rate. Studies have shown that negative clinical outcome with regard to pain control includes decreases in vital capacity and alveolar ventilation, pneumonia, tachycardia, hypertension, myocardial ischemia, transition into chronic pain, poor wound healing, and psychological sequelae .

Pain has been found to be one of the three most common medical causes of delayed/aborted discharge after ambulatory surgery, the other two being drowsiness and postoperative nausea/vomiting. Despite progress that has been made with regard to postoperative pain control, and the development of new standards for pain control, many patients continue to experience intense pain after surgery .

Recent advances in the understanding of the particularities of central sensitization indicate that it plays an important role in post surgical and post traumatic pain and therefore should be avoided


Options:
A: Arm Label: Morphine 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Morphine | Arm Label: Morphine 0.5; Type: EXPERIMENTAL; Interventions: Drug: Morphine | Arm Label: Dexketoprofen & Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexketoprofen, Drug: Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine 0.5, Morphine 1 mg | Intervention Type: DRUG; Name: Dexketoprofen; Assigned to Arm(s): Dexketoprofen & Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dexketoprofen & Placebo
B: Arm Label: Sumatriptan; Type: EXPERIMENTAL; Interventions: Drug: Sumatriptan, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sumatriptan, Other: Placebo | Intervention Type: DRUG; Name: Sumatriptan; Assigned to Arm(s): Placebo, Sumatriptan | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Sumatriptan
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous Parecoxib ('Dynastat' Pfizer) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous Parecoxib ('Dynastat' Pfizer) | Intervention Type: DRUG; Name: Intravenous Parecoxib ('Dynastat' Pfizer); Assigned to Arm(s): 1, 2
D: Arm Label: Lyrica; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Lyrica | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Medical Abortion Provided by Midlevel Providers or Physicians
Brief Summary: The physical examination before an abortion is usually performed by a physician. However, in many countries access to physicians is limited. To increase access to safe abortion this study wishes to examine if midlevel providers such as specially trained midwives can provide safe abortion services. Midwives in study were specially trained to perform early pregnancy ultrasound and if needed to consult a physician. The midwife then provided the abortion service as well as the contraceptive advice. Women were randomized to receive the service from a midwife or a physician.


Options:
A: Arm Label: sublingual misoprostol; Type: EXPERIMENTAL; Interventions: Drug: sublingual misoprostol | Arm Label: vaginal misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: vaginal misoprostol | Intervention Type: DRUG; Name: sublingual misoprostol; Assigned to Arm(s): sublingual misoprostol | Intervention Type: DRUG; Name: vaginal misoprostol; Assigned to Arm(s): vaginal misoprostol
B: Arm Label: midwife; Type: EXPERIMENTAL; Interventions: Other: Midwife | Arm Label: Physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Midwife; Assigned to Arm(s): midwife
C: Intervention Type: DRUG; Name: 800 mcg misoprostol via oral or buccal administration; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Induced Hypertension for Treatment of Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage
Brief Summary: The objective of this multi-centre, randomized controlled trial is to investigate the outcome after induced hypertension versus no induced hypertension in patients with delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH), and to assess whether induced hypertension results in improved cerebral blood flow (CBF) as measured by means of perfusion-CT.


Options:
A: Arm Label: Candesartan Cilexetil; Type: EXPERIMENTAL; Interventions: Drug: Candesartan Cilexetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Candesartan Cilexetil; Assigned to Arm(s): Candesartan Cilexetil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Induced hypertension; Type: ACTIVE_COMPARATOR; Interventions: Other: Induced hypertension | Intervention Type: OTHER; Name: Induced hypertension; Assigned to Arm(s): Induced hypertension
C: Intervention Type: DRUG; Name: Labetalol Hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metoprolol tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Hydralazine Hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Glycerol Trinitrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Phentolamine mesylate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nicardipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Urapidil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Esmolol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Enalaprilat; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nitroprusside; Assigned to Arm(s): N/A
D: Arm Label: Clazosentan; Type: EXPERIMENTAL; Interventions: Drug: Clazosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Clazosentan; Assigned to Arm(s): Clazosentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors (COACH)
Brief Summary: The overall goal of the COACH study is to conduct a comparative effectiveness trial to assess the effectiveness of trained, participant-designated health coaches versus traditional health education efforts on cancer screening among African American older adults. We hypothesize that members of older adults' extended families can be trained to be effective coaches who support them through the cancer control spectrum, i.e., prevention, screening, diagnosis and treatment. This research objective is guided by the theoretical model of the PRECEDE-PROCEED conceptual framework that has been widely adopted in health promotion. The target jurisdictions for this study are Baltimore City (BC) and Prince George's County (PGC), Maryland. The study is anchored in community-based participatory research (CBPR) principles, involving community members in all its phases. The CBPR component is guided by Community Advisory Groups (CAGs) representing key stakeholders in the two jurisdictions. The CAGs are essential in determining the questions included in data collection instruments, mechanisms of recruitment, interpretation of findings, and dissemination of results within the target communities.


Options:
A: Intervention Type: DEVICE; Name: online health information journal; Assigned to Arm(s): N/A
B: Arm Label: Motivational SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational SMS | Arm Label: Travel Voucher; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational SMS, Behavioral: Travel Voucher | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational SMS; Assigned to Arm(s): Motivational SMS, Travel Voucher | Intervention Type: BEHAVIORAL; Name: Travel Voucher; Assigned to Arm(s): Travel Voucher
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity Information (DVD); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DVD | Arm Label: High Intensity Information (Promotora); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Promotora | Intervention Type: BEHAVIORAL; Name: DVD; Assigned to Arm(s): Low Intensity Information (DVD) | Intervention Type: BEHAVIORAL; Name: Promotora; Assigned to Arm(s): High Intensity Information (Promotora)
D: Arm Label: Printed Educational Material (PEM) only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Printed Educational Materials (PEM) | Arm Label: Coach Training (COACH); Type: EXPERIMENTAL; Interventions: Behavioral: Coach Training (COACH) | Intervention Type: BEHAVIORAL; Name: Coach Training (COACH); Assigned to Arm(s): Coach Training (COACH) | Intervention Type: BEHAVIORAL; Name: Printed Educational Materials (PEM); Assigned to Arm(s): Printed Educational Material (PEM) only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of S.Cerevisiae vs Placebo on the Improvement of Gastrointestinal Disorders,Especially During Irritable Bowel Syndrome. Randomized, Double-blind Study
Brief Summary: The main purpose of this study is the effect of the probiotic yeast Saccharomyces cerevisiae CNCM I-3856 on abdominal pain or intestinal discomfort in patients presenting with the irritable bowel syndrome (IBS)


Options:
A: Arm Label: Probiotics supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Saccharomyces cerevisiae CNCM I-3856; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Saccharomyces cerevisiae CNCM I-3856 | Intervention Type: DIETARY_SUPPLEMENT; Name: Saccharomyces cerevisiae CNCM I-3856; Assigned to Arm(s): Saccharomyces cerevisiae CNCM I-3856 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus GG (probiotic ) | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus GG (probiotic ); Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Probiotics(Medirac) 10/mosapride 10mg; Type: EXPERIMENTAL; Interventions: Drug: Probiotics (Medirac) | Arm Label: Probiotics(Medirac) 15/mosapride 10mg; Type: EXPERIMENTAL; Interventions: Drug: Probiotics (Medirac) | Arm Label: Probiotics(Medirac) 15/mosapride 15mg; Type: EXPERIMENTAL; Interventions: Drug: Probiotics (Medirac) | Arm Label: Probiotics(Medirac) 30/mosapride 15mg; Type: EXPERIMENTAL; Interventions: Drug: Probiotics (Medirac) | Arm Label: Probiotics(Medirac) placebo/mosapride placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Probiotics (Medirac) placebo/mosapride placebo | Intervention Type: DRUG; Name: Probiotics (Medirac); Assigned to Arm(s): Probiotics(Medirac) 10/mosapride 10mg | Intervention Type: DRUG; Name: Probiotics (Medirac); Assigned to Arm(s): Probiotics(Medirac) 15/mosapride 10mg | Intervention Type: DRUG; Name: Probiotics (Medirac); Assigned to Arm(s): Probiotics(Medirac) 15/mosapride 15mg | Intervention Type: DRUG; Name: Probiotics (Medirac); Assigned to Arm(s): Probiotics(Medirac) 30/mosapride 15mg | Intervention Type: DRUG; Name: Probiotics (Medirac) placebo/mosapride placebo; Assigned to Arm(s): Probiotics(Medirac) placebo/mosapride placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Controlled, Open Label, Clinical Trial to Study if Rosuvastatin Use Improves the Coagulation Profile in Patients With Venous Thrombosis
Brief Summary: Epidemiological studies have shown a 2-3 fold increased long-term risk of arterial cardiovascular disease after venous thrombosis, most predominant in the first year following initial venous thrombosis. The results of recent observational studies that showed 40-50% risk reductions for first venous thrombosis occurrence when using a statin are in this aspect promising. The results are also somewhat surprising, because the mechanism behind this effect is unclear. Dyslipidemia may be the most plausible explanation to be considered. However, as dyslipidemia is not related to an increased risk of venous thrombosis, it is unlikely that statins decrease venous thrombosis risk by lipid lowering activities. Recent observations indicate that coagulation can activate the initial formation of atherosclerosis. Our hypothesis is therefore that the coagulation profile in persons with venous thrombosis is improved when using a statin, ultimately leading to less atherosclerosis: another well known property of statin use.


Options:
A: Arm Label: Ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Doubling statin dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin 40 mg or atorvastatin 20 mg, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): Ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin 40 mg or atorvastatin 20 mg; Assigned to Arm(s): Doubling statin dose | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: atorvastatin 10 mg or simvastatin 20 mg; Assigned to Arm(s): Doubling statin dose, Ezetimibe/simvastatin, Rosuvastatin
B: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Arm Label: Experimental: Rosuvastatin + enoxaparin arm; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin 20mg/d for 14days | Arm Label: enoxaparin only; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin only | Intervention Type: DRUG; Name: Rosuvastatin 20mg/d for 14days; Assigned to Arm(s): Experimental: Rosuvastatin + enoxaparin arm | Intervention Type: DRUG; Name: enoxaparin only; Assigned to Arm(s): enoxaparin only
D: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma
Brief Summary: Sorafenib and pazopanib are both effective and promising treatments for advanced Renal Cell Carcinoma (RCC). Both drugs are registered for this indication. No prospective comparative data in advanced RCC (or other indications) have been published. A search in the clinicaltrials.gov database did not reveal any planned or ongoing studies. As sequential therapy is now the standard of treatment for advanced RCC it is important to evaluate in clinical trials what the value of different sequential strategies is. This needs to be done every time new agents are introduced into the treatment armamentarium. As there are no data yet on the sequential use of sorafenib followed by pazopanib or vice versa, this sequence, however, will most certainly be used in daily practice, it is required to examine efficacy and safety of this sequential approach in a clinical trial in a randomized setting.

Therefore, the investigators have designed an open randomized study in patients not previously treated for advanced RCC. Suitable patients will be randomized (1:1) in 2 groups.


Options:
A: Arm Label: Atezolizumab + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Atezolizumab + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab + Bevacizumab | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Arm Label: Sorafenib-sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib-sunitinib | Arm Label: Sunitinib-sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib-sorafenib | Intervention Type: DRUG; Name: Sorafenib-sunitinib; Assigned to Arm(s): Sorafenib-sunitinib | Intervention Type: DRUG; Name: Sunitinib-sorafenib; Assigned to Arm(s): Sunitinib-sorafenib
C: Arm Label: SUNITINIB MALATE.; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib malate | Intervention Type: DRUG; Name: Sunitinib malate; Assigned to Arm(s): SUNITINIB MALATE.
D: Arm Label: Sorafenib followed by pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib+Pazopanib | Arm Label: Pazopanib followed by Sorafenib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib+Sorafenib | Intervention Type: DRUG; Name: Sorafenib+Pazopanib; Assigned to Arm(s): Sorafenib followed by pazopanib | Intervention Type: DRUG; Name: Pazopanib+Sorafenib; Assigned to Arm(s): Pazopanib followed by Sorafenib

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma
Brief Summary: Sorafenib and pazopanib are both effective and promising treatments for advanced Renal Cell Carcinoma (RCC). Both drugs are registered for this indication. No prospective comparative data in advanced RCC (or other indications) have been published. A search in the clinicaltrials.gov database did not reveal any planned or ongoing studies. As sequential therapy is now the standard of treatment for advanced RCC it is important to evaluate in clinical trials what the value of different sequential strategies is. This needs to be done every time new agents are introduced into the treatment armamentarium. As there are no data yet on the sequential use of sorafenib followed by pazopanib or vice versa, this sequence, however, will most certainly be used in daily practice, it is required to examine efficacy and safety of this sequential approach in a clinical trial in a randomized setting.

Therefore, the investigators have designed an open randomized study in patients not previously treated for advanced RCC. Suitable patients will be randomized (1:1) in 2 groups.


Options:
A: Arm Label: RAD001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): RAD001 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Arm Label: Sorafenib followed by pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib+Pazopanib | Arm Label: Pazopanib followed by Sorafenib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib+Sorafenib | Intervention Type: DRUG; Name: Sorafenib+Pazopanib; Assigned to Arm(s): Sorafenib followed by pazopanib | Intervention Type: DRUG; Name: Pazopanib+Sorafenib; Assigned to Arm(s): Pazopanib followed by Sorafenib
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: temsirolimus (Torisel) | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: temsirolimus (Torisel); Assigned to Arm(s): 2
D: Arm Label: everolimus 1L/sunitinib 2L; Type: EXPERIMENTAL; Interventions: Drug: everolimus, Drug: sunitinib | Arm Label: sunitinib 1L/everolimus 2L; Type: ACTIVE_COMPARATOR; Interventions: Drug: everolimus, Drug: sunitinib | Intervention Type: DRUG; Name: everolimus; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L

Answer: B